Market closedNon-fractionalADR
Immunocore/IMCR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Immunocore
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.
Ticker
IMCR
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Abingdon, United Kingdom
Employees
497
Website
www.immunocore.com
Immunocore Metrics
BasicAdvanced
$2.4B
Market cap
-
P/E ratio
-$1.20
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$2.4B
52-week high
$76.98
52-week low
$41.01
Average daily volume
13
Financial strength
Current ratio
5.963
Quick ratio
5.936
Long term debt to equity
121.698
Total debt to equity
121.698
Management effectiveness
Return on assets (TTM)
-7.80%
Return on equity (TTM)
-17.04%
Return on investment (TTM)
-9.40%
Valuation
Price to revenue (TTM)
9.215
Price to book
6.774
Price to tangible book (TTM)
6.813
Growth
Revenue change (TTM)
34.03%
Earnings per share change (TTM)
-11.37%
3-year revenue growth (CAGR)
86.24%
What the Analysts think about Immunocore
Analyst Ratings
Majority rating from 17 analysts.
Immunocore Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$71M
-71.73%
Net income
-$24M
-55.80%
Profit margin
-34.60%
56.35%
Immunocore Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.37
$0.05
-$0.40
-$0.49
-
Expected
-$0.41
-$0.36
-$0.28
-$0.36
-$0.47
Surprise
-9.77%
-113.67%
45.08%
35.45%
-
Immunocore News
AllArticlesVideos
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
GlobeNewsWire·2 months ago
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
GlobeNewsWire·2 months ago
Immunocore to present at the Jefferies Global Healthcare Conference
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Immunocore stock?
Immunocore (IMCR) has a market cap of $2.4B as of July 26, 2024.
What is the P/E ratio for Immunocore stock?
The price to earnings (P/E) ratio for Immunocore (IMCR) stock is 0 as of July 26, 2024.
Does Immunocore stock pay dividends?
No, Immunocore (IMCR) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Immunocore dividend payment date?
Immunocore (IMCR) stock does not pay dividends to its shareholders.
What is the beta indicator for Immunocore?
Immunocore (IMCR) does not currently have a Beta indicator.
Buy or sell Immunocore stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.